通过调节PrPC信号的营养活动来减轻AβO毒性
Shuya Liu1, Shiwei Li1, Jirong Lin2
1MOE Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection Technology for Food Safety, College of Chemistry, Fuzhou University, Fuzhou 350116, P. R. China.
Journal of the American Chemical Society
|May 18, 2022
概括
这项研究探讨了针对细胞质蛋白 (PrPC) 来治疗阿尔茨海默病 (AD). 一种由aptamer诱导的二元化策略调节PrPC信号,降低粉样β寡合体毒性和神经炎症,用于潜在的新型AD疗法.
科学领域:
- 神经科学
- 生物化学
- 药理学
背景情况:
- 目前针对粉样β寡合体 (AβO) 的阿尔茨海默病 (AD) 疗法表现出有限的成功.
- 细胞蛋白 (PrPC) 作为AβO的细胞表面受体,调解神经毒性.
- 对于其神经保护功能来说, PrPC二元化至关重要.
研究的目的:
- 研究调节PrPC受体活性作为一种新的阿尔茨海默病治疗方法.
- 探索一种由胺诱导的二聚化 (AID) 策略的有效性,以准PrPC信号.
主要方法:
- 开发了一种由胺诱导的二元化 (AID) 策略,以强制执行PrPC二元化.
- 评估了AID策略干扰AβO-PrP相互作用的能力.
- 评估了AID对AβO诱导的线粒体功能障碍,细胞亡和神经炎症的影响.
主要成果:
- 通过调节PrPC信号,AID策略成功地减轻了AβO毒性.
- 艾滋病促进了神经保护性PrPC的分泌,并预防了AβO诱导的线粒体功能障碍和亡.
- 这种策略减少了炎症性细胞因子分泌,缓解了神经炎症.
结论:
- 通过AID准PrPC信号是阿尔茨海默病的一个有前途的新疗法.
- 调节PrPC活动为克服当前阿尔茨海默病治疗的局限性提供了一个潜在的策略.
- 这种方法可以通过解决神经保护和神经炎症来开发新的AD疗法.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.9K
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.1K
相关概念视频
01:12GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K